|
|
|
23.10.26 - 21:33
|
Novartis Sector Perform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Novartis auf "Sector Perform" mit einem Kursziel von 120 Franken belassen. Die Präsentation der Daten aus Phase-3-Studien REMODEL-1/-2, in denen Remibrutinib in Kombination mit ......
|
|
|
|
|
|
|
23.10.26 - 17:48
|
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile (GlobeNewswire EN)
|
|
|
Basel, October 23, 2026 – Novartis today presented positive results from the pivotal Phase III REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis (RMS) showing that remibrutinib, a highly selective and efficacious oral Bruton's tyrosine kinase (BTK) inhibitor, demonstrated superior relapse control and a clinically meaningful delay in disease progression versus teriflunomide with no liver safety signal.¹˒⁶˒⁷ The study results were presented during a late-breaking session at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting, and were published simultaneously in The Lancet.¹˒⁸...
|
|
|
|
|
|
|
|
|
23.10.26 - 13:33
|
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence (GlobeNewswire EN)
|
|
|
Basel, October 23, 2026 – Novartis today announced results from the six-year follow-up analysis of the Phase III NATALEE trial, reporting positive, clinically meaningful overall survival (OS) data with Kisqali® (ribociclib) plus endocrine therapy (ET) compared to ET alone1. The study was in the broadest early breast cancer (eBC) population of patients with stage II and III HR+/HER2- early breast cancer at high risk of recurrence, including those with high-risk node-negative (N0) disease and all node-positive patients1,2. Kisqali plus ET reduced the risk of death by nearly 20% (19.1%) compared to ET alone (HR=0.809; 95% CI: 0.661-0.989), with consistent overall survival benefit observed across all key subgroups1. These late-breaking results will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2026....
|
|
|
22.10.26 - 04:16
|
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight (ZeroHedge)
|
|
|
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight
Authored by Paul D. Thacker via The DisInformation Chronicle,
New York Times reporter Sheryl Gay Stolberg wrote one of the most hilarious, misleading pieces I've seen in recent months, castigating the NIH for a new vaccine injury clinic based on a leaked statement by Jack Leslie, a senior advisor to the PR firm Weber Shandwick which represents most major vaccine manufacturers.
I'm not joking. This is the journalism I get for my paid subscription to the New York Times.
Like most senior executives at the global PR firm Weber Shandwick, Jack Leslie makes buckets of money helping corporations sell themselves and their products to the American public. In the last handful of years, Weber Shandwick's clients have included the bulk of the global vaccine giants including Pfizer, Moderna, GSK, Sanofi, Novartis, and Eli Lilly.
But when he's not raking in oodles of cash repping corporate America, Leslie also takes on some unpaid healthcare...
|
|
|
|
|
|
|
21.10.26 - 17:01
|
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR) (GlobeNewswire EN)
|
|
|
Basel, October 21, 2026 – Novartis announced today that the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucocorticoids or who experience relapse during glucocorticoid taper. With this approval, Cosentyx becomes the first and only interleukin-17A (IL-17A) inhibitor approved in Europe for adults with PMR.1...
|
|
|
20.10.26 - 16:42
|
Novartis Neutral (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Novartis vor weiteren Studienerkenntnissen auf "Neutral" mit einem Kursziel von 116 Franken belassen. Phase-3-Studienergebnisse zum Medikament Remibutinib gegen die schubförmig-remittierende ......
|
|
|
20.10.26 - 12:03
|
Unimed Appoints Sune Svenningsen as Chief Executive Officer (Business Wire)
|
|
|
International healthcare executive brings nearly 30 years of experience leading global supply, operations and distribution businessesATHENS, Greece--(BUSINESS WIRE)--Universal Maritime Solutions (“Unimed” or “the Company”), a leading provider of maritime medical supply, health compliance and crew wellbeing solutions and a portfolio company of ZCG Private Equity, the private equity fund management platform of Z Capital Group, LLC (“ZCG”), today announced the appointment of Sune Svenningsen as Chief Executive Officer.
Mr. Svenningsen brings nearly 30 years of international leadership experience across healthcare supply chains, operations, distribution and business transformation. He joins Unimed from International SOS, where he held several senior roles, including Chief Executive Officer of its Supply Division and Chief Operating Officer of its Medical Services business. Previously, he held leadership positions at Novartis and Missionpharma, overseeing operations across Asia-Pacific, the Middle ...
|
|
|
|
|
|
|
|
|
|
|
|
|
16.10.26 - 09:12
|
Novartis Sector Perform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Novartis vor Zahlen für das dritte Quartal auf "Sector Perform" mit einem Kursziel von 120 Franken belassen. Der Pharmakonzern dürfte die Markterwartungen in etwa erfüllen, schrieb ......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
